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Fourteen years of evolution of ESMO
Guidelines: from the minimum
recommendations to the Consensus
Conference-derived guidelines
introduction
During the last two decades various Clinical Practice Guidelines
(CPGs) have been developed by professional associations,
institutions or medical societies at an international, national or
regional level.
CPGs are defined as ‘systematically developed statements to
assist practitioner and patient decisions about appropriate
health care for specific clinical circumstances’ [1]. CPGs are
based on the evidence-based medicine system and are a tool for
transferring evidence from clinical research into practice and
for influencing practitioner’s attitude [2].
As a matter of fact, CPGs are intended: (i) to assist
practitioners in appropriate clinical decision making; (ii) to
improve quality of healthcare and outcomes for patients; and
(iii) to influence national policies for efficient allocation of
resources and for better delivery systems [3]. As Eisenberg and
Power pointed out, CPGs are intended to provide the right
care, at the right time, for the right person and in the right way
[4].
The development process of CPGs in not homogeneous
among the internationally available guidelines. The differences
are mainly related to several methodological issues, such as
multidisciplinarity, production process, etc. Not all CPGs are
produced through a systematic review of evidence, a process
that consists of (i) formulation of a clinical question/
problem; (ii) identification of relevant papers by support
staff and an expert taskforce; (iii) tabulation and synthesis
of evidence by methodological experts; and (iv) process of
CPGs, drafting by the experts. On the other hand,
some CPGs are also developed through a narrative literature
search.
Heterogeneity in the development of CPGs is a vital issue. In
a recent report, nine well-known CPGs (ASCO, ESMO, NICE,
SIGH, START, NHMRC, NCI, NCCN and CCO) and three
representative tumors (advanced breast, lung and colon cancer)
were selected and scrutinized. Results have shown that a diverse
heterogeneity in development, structure, target user and
endpoints was prominent among them [5].
CPGs should be properly and effectively implemented and
disseminated in order to be adequately incorporated into daily
clinical practice. This can be achieved by: (i) direct mailing; (ii)
publication in journals or newsletters; (iii) organization or
sponsoring of scientific events; (iv) training by opinion leaders;
(v) publicizing to patients or the public; and (vi) integration in
recertification or licensing examinations.
Assessment of the quality of the process of development and
reporting of CPGs is of paramount importance taking into
account their benefits, harm, costs and practicalities. An
example is the AGREE Instrument (Appraisal of Guidelines
Research and Evaluation) that was established in 1998. In
addition, due to both cultural and organizational differences
that could exist among countries, a ‘trans-contextual
adaptation’ strategy has been suggested by the ADAPTE
framework [6].
historical development of ESMO CPGs
1998
The original idea for the creation of the ESMO Clinical
Guidelines came from Professor Heine H. Hansen via the
Central European Task Force in 1998. In particular, he
visualized the need for clinical recommendations that might be
more practical in daily use. This was supported at a meeting of
the ESMO national representatives, who felt that the
development of guidelines would contribute to the standing of
medical oncology in Europe.
1999
Thus, in 1999, the ESMO Guidelines Task Force was
constituted. Initially, the group began with a chairman
(R. Stahel, Switzerland), a central coordinator (L. Jost,
Switzerland), an ESMO officer (M. C. Reinhart) and five
members (J. Herrstedt, Denmark; O. Kloke, Germany;
N. Pavlidis, Greece; G. Purkalne, Latvia; and S. Jelic,
Yugoslavia). During the next 5 years more members joined the
task force (J. Berg, Sweden; R. Greil, Austria; V. Kataja, Finland;
and J. Oliveira, Portugal).
2006
Since 1 January 2006, the Guidelines Task Force has been an
independent group—the ESMO Guidelines Working Group
(GLWG)—under the new ESMO Education Committee
structure. It consists of: (i) an Editorial Board with a chairman
(N. Pavlidis, Greece), three members (R. Stahel, Switzerland;
H. Hansen, Denmark; and S. Jelic, Serbia), an Annals of
Oncology executive (L. Rowett, UK) and an ESMO Coordinator
(P. Minotti); and (ii) the seven Subject Editors responsible for
the topics, the authors, the revision of the manuscripts and the
presentation and discussion of final drafts with the editorial
board (M. Castiglione, Switzerland; J. Oliveira, Portugal;
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E. Felip, Spain; V. Kataja, Finland; M. Dreyling, Germany;
L. Jost, Switzerland; and F. Roila, Italy).
2008
In 2008 the GLWGmade some changes as follows: (i) an Editorial
Board with a Chairman (N. Pavlidis, Greece), two members (R.
Stahel, Switzerland; and H. Hansen, Denmark), an Annals of
Oncology executive (L. Rowett, UK) and an ESMO Coordinator
(R. Vecchi) and (ii) nine Subject Editors: M. Castiglione,
Switzerland for breast and gynecological cancer; M. Dreyling,
Germany for hematological malignancies; E. Felip, Spain for lung
and head/neck cancer; P. Casali, Italy for sarcomas; V. Kataja,
Finland for genitourinary cancer; A. Cervantes, Spain for
gastrointestinal cancer; F. Roila, Italy for supportive care; S. Jelic,
Serbia for liver, pancreatic cancer and neuroendocrine tumors;
and G. Pentheroudakis, Greece for rare tumors.
2009
In 2009 F. Cardoso (Lisbon, Portugal) was appointed as the
Subject Editor for breast cancer.
2011
In 2011 the Chairmanship has changed. Andres Cervantes
became the Chairman of the ESMO GLWG, and N. Pavlidis
became the Co-Chairman. In addition, C. Sessa (Bellinzona,
Switzerland) for gynecological cancer and C. Bramley as the
ESMO Guidelines and Publishing Manager.
the structure and function of the ESMO
GLWG through the years
The structure of the GLWG consists of: (i) the Editorial Board;
(ii) the Subject Editors; (iii) the authors; and (iv) the reviewers
(five reviewers for each CPG). Both authors and reviewers are
on a multidisciplinary platform and should all be ESMO
Faculty members (Figure 1). The process of ESMO CPG
development is demonstrated in Table 1. Nearly 14 years after
the inception of the ESMO Guidelines Task Force, 54 clinical
guidelines (GLs) were freely available on the ESMO website and
in Annals of Oncology.
The initial vision of ESMO GLs was not to compete with
other national or international GLs, but to be complementary
recommendations to other existing guidelines and to continue
to be used in day-to-day practice; in other words, ESMO GLs
were based on a philosophy of providing basic and practical
information to oncologists and protecting them from ‘what and
how not to do things’. Therefore, ESMO GLs were at that time
called ‘ESMO Minimum Clinical Recommendations’ and
included GLs: (i) of a short size (1–3 pages); (ii) annually
published in Annals of Oncology and on the ESMO website;
(iii) produced by and dedicated to medical oncologists; and
(iv) covering most tumor types.
Since 2006 ESMO decided to expand the size of GLs and to
call them simply ‘ESMO Clinical Recommendations’. In 2007
ESMO introduced Consensus Conferences to address
Editorial  Board 
Chairman 
2 Members  
1  Ann.  Oncology  Executive 
1  ESMO  Officer 
Subject  Editors (10) 
1. Breast  
2. Gynecological  Cancer 
3. Hematological  Malignancies 
4. Head/Neck and Lung Cancer 
5. Urogenital  Cancer 
6. Upper and lower gastrointestinal tract cancers 
7. Pancreato-hepatobiliary  cancers 
8. Sarcomas 
9. Supportive Care 
10. Rare  tumors 
Authors
Reviewers 
5 ESMO Faculty Members per topic on  
A multidisciplinary  platform  
Figure 1. The structure of the EMSO Guidelines Working Group.
Table 1. ESMO Guidelines development process
ESMO GLWG (Select topics)
Y
Subject Editors (SE) (Invite authors)
Y
Authors (send manuscript to SEs)
Y
SEs (select reviewers)
Y
Reviewers (return manuscript to SEs)
Y
SEs (send manuscript to Editors for first ‘make decision’ process)
Y
Editors (return manuscript to SEs)
Y
SEs (notify authors)
Y
Authors (accept final comments)
Y
SEs (send manuscript to Editors for final approval)
Y
Editors (make final decision)
editorial Annals of Oncology
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preselected questions on specific tumor types. The objective of
these conferences is to address difficult issues using a much
wider input from the oncology community by utilizing 30–40
experts. Up to now eight Consensus Conferences have taken
place in various European cities (Table 2). Recently, it has also
been proposed that ESMO GLs will be called ‘ESMO Clinical
Practice Guidelines (CPGs)’ and all GLs will be available on the
ESMO website and only the updated ESMO CPGs will be
published annually in Annals of Oncology (Table 3). ESMO
Consensus Conference-derived CPGs will also appear in Annals
of Oncology [7–10].
Based on the lessons learned from the first Consensus
Conferences, a detailed Standard Operating Procedures
platform has been developed and will be implemented from
2011 onwards.
implementation of ESMO CPGs
Successful establishment of guidelines requires both adequate
implementation and sufficient dissemination. Effective
Table 2. Consensus meeting-derived ESMO CPGs
Date Event Venue Funded by
October 2007 Soft tissue sarcomas and GIST Lugano, Switzerland Conticanet
May 2008 Testicular cancer Munich, Germany ESMO (EIS)
May 2009 Communication skills Kappel am Albis, Switzerland Swiss Cancer League
June 2009 Antiemetics Perugia, Italy MASCC/ESMO
November 2009 Sarcomas (STS) Lugano, Switzerland Conticanet
November 2009 Sarcomas (bone) Lugano, Switzerland Eurobonet
May 2010 Lung cancer Lugano, Switzerland ESMO, San Salvatore
Foundation
September 2010 Colorectal cancer Lugano, Switzerland ESMO
June 2011 Malignant lymphoma Lugano, Switzerland ESMO
Table 3. ESMO Guidelines evolution (1998–2011)
Year Name
1998 ESMO Minimum Clinical
Recommendations
2006 ESMO Clinical Recommendations
2010 ESMO Clinical Practice Guidelines
Table 4. Universal geographical breakdown of usage (2008–2010)
Country Total usage %
USA 103 870 13
Italy 61 955 8
Switzerland 47 631 6
Germany 47 073 6
UK 40 696 5
Spain 35 863 4
India 29 056 4
Mexico 25 987 3
China 25 924 3
France 22 877 3
Brazil 21 932 3
Canada 20.115 2
Portugal 17 530 2
Egypt 15 541 2
Turkey 15 338 2
Japan 14 709 2
Australia 14 692 2
Romania 14 156 2
Others 232 181 28
Total 807 137 100
Figure 2. Guidelines downloads overview (2009–2010). Total usage
during the first 6 months post-publication.
Table 5. Geographical breakdown of usage by continent (2008–2010)
Continent Total usage %
Europe 388 047 48
America
North 123 985 15.5
South 55 600 7.0
Central 32 696 4.0
Asia 146 187 18.0
Africa 26 336 3.5
Australasia 16 902 2.0
Japan 14 713 1.8
Unknown 2671 0.3
Total 807 137 100
Annals of Oncology editorial
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implementation of CPGs facilitates knowledge uptake and
more efficient patient-focused care.
The targeted health professionals for ESMO CPGs are mainly
medical oncologists. The two methodological tools used to
implement ESMO CPGs are the availability of CPGs in Annals
of Oncology and the ESMO website, and the questionnaire
administered (by a electronic answering system) to all attendees
of the ESMO Guidelines Interactive Sessions held at every
ESMO Congress. From 2005 and up to 2010 all ESMO CPGs
were published annually in the Annals of Oncology, but they
also appeared on the ESMO website. From 2011 onwards,
Annals of Oncology will only publish the updated CPGs and the
Consensus Conference-derived CPGs, while the ESMO website
will host all available ESMO CPGs.
The number of downloads from data extracted form the
Oxford Journals usage statistics through the years showed an
exponential increase (Figure 2). The five most downloaded
CPGs in 2008–2010 were breast cancer, non-small cell lung
cancer, gastric cancer, epithelial ovarian cancer and colon
cancer. An analysis of the geographical distribution of usage of
CPGs published in Supplements of the Annals of Oncology from
2008 to 2010 (volume 19/suppl 2, volume 20/suppl 4, volume
21/suppl 5) is also available.
Universally the three most highly ranked countries are the
USA, Italy and Switzerland. Geographical breakdown by
continent showed that Europe is by far the most highly ranked
continent accounting for almost the half of the downloads
(Table 5). It is also interesting to point out that the total usage
in North America is mostly attributed to the USA (84%) and
only 16% to Canada. Concerning the European geographical
distribution, Italy, Switzerland and Germany are the three
nations with the highest percentage usage (Table 6).
Another tool used to evaluate the spectrum of implementation
was a survey/questionnaire given during the ESMO Congresses
(Table 7). The first three questions, asked at the onset, were
related to audience exposure to ESMO clinical recommendations,
while the seven questions asked at the end of the session were
taken from the survey of Tunis et al. [11]. This questionnaire was
prepared to assess the familiarity, confidence and attitudes
relating to ESMO CPGs. More than 80% of the responders feel
that ESMO CPGs are helpful for their daily practice, 85% believe
that they are also a good educational tool, and 95% think that
they are intended to improve patients’ quality of care.
dissemination of ESMO CPGs
During the last several years ESMO CPGs have been
disseminated using different methodological tools. The first
tool is the translation of ESMO CPGs into various languages.
Up to now they have been translated into 13 languages
(Bulgarian, Chinese, French, German, Greek, Italian, Japanese,
Latvian, Polish, Portuguese, Romanian, Russian and Spanish).
The second tool is the organization of the ESMO interactive
sessions during the ESMO Congresses. In these 2 h interactive
events 2–3 cases on various tumors or other oncology topics are
presented by a young medical oncologist and discussed by an
expert European oncologist based on the ESMO CPGs. Each
case is followed by three multiple-choice questions which
should first be answered by the audience through an electronic
Table 6. Geographical breakdown of usage in Europe (2008–2010)
Country Total usage %
Italy 61 955 16
Switzerland 47 631 12
Germany 47 073 12
UK 40 696 10
Spain 35 863 9
France 22 877 6
Portugal 17 530 5
Romania 14 156 4
Greece 10 499 3
Poland 10 284 3
Belgium 9785 3
The Netherlands 7503 2
Others (35 countries) 62 195 16
Total 388 047 100
Table 7. Audience questionnaire administered during the ESMO
Congresses
Question Response
1. How many time have you
attended the ESMO CR
sessions during ESMO
congress (2000–2006)?
Once
Twice
Three times
Four times
2. Within the last year how
many times have you
consulted the ESMO CRs?
Not at all
Once
<10 times
>10 times
3. What is your preferred access
to ESMO CRs?
Annals of Oncology
ESMO website
4. Do you think ESMO CRs are
helpful source of advice?
Yes
No
Don’t know/no answer
5. Do you think ESMO CRs are
good educational tools?
Yes
No
Don’t know/no answer
6. Do you think ESMO CRs are
intended to improve quality
of care?
Yes
No
Don’t know/no answer
7. Do you think ESMO CRs are
intended to cut healthcare are
costs?
Yes
No
Don’t know/no answer
8. Do you think ESMO CRs will
increase litigation or
disciplinary action?
Yes
No
Don’t know/no answer
9. Do you think ESMO CRs
reduce physicians’ autonomy
and are oversimplified or
‘cookbook’ medicine?
Yes
No
Don’t know/no answer
10. Do you think ESMO CRs are
impractical and too rigid to
apply to individual patients?
Yes
No
Don’t know/no answer
CRs, clinical recommendations.
editorial Annals of Oncology
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voting system. All these sessions are well attended and it is
worth mentioning that at the 35th ESMO Congress in Milan
in 2010, the audience had increased up to 3200 attendees
(Table 8).
The third tool is the presentation of ESMO CPGs by
members of the GLWG in Congresses Symposia or other
scientific events both in and outside Europe.
The last tool of dissemination of ESMO CPGs is the
publication of editorials or articles in oncology journals. The
aims are to increase the awareness of the European and
international oncological societies about the availability, the
quality and the utility of ESMO CPGs.
future developments
ESMO is introducing new ideas on CPG implementation and
dissemination by producing pocket-sized booklets and mobile
apps. Pocket-sized booklets will present the key information
from CPG/Consensus manuscripts in a quick references format
including treatment algorithms and all recommendations.
Mobile apps will present the information in pocket versions
in SmartPhone and other app formats for use on mobile
devices.
In addition, ESMO is aiming to produce CPG slide-sets for
use by ESMO members as a teaching resource. Good clinical
guidelines can have a deep impact on the quality of cancer care
in a community. Moreover, if the recommendations provided
are well implemented, this may eventually have a potential
benefit in cancer outcomes. For this reason, ESMO is
committed to produce high quality, evidence-based guidelines
to offer a useful tool to the whole oncology community. Our
aim is to help in keeping clinical practice within the current
understanding and best science in a multidisciplinary setting.
To provide such an instrument, a tremendous effort has to be
made and a long, controlled process has to be organized every
year with the cooperation of authors, reviewers, Subject Editors
and ESMO officers. The final product of this cooperative
undertaking has to benefit not only oncologists, helping them
in optimal clinical practice, but also patients, giving them the
opportunity for the best possible outcomes.
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Table 8. ESMO Interactive Guidelines Sessionsa
Date and place of
Congress
Topics discussed Average score
2000, Hamburg Colon Cancer 3.78
NSCLC
Testicular Cancer
2002, Nice Cancer of Unknown
Primary
4.05
Ovarian Cancer
Prostate Cancer
2004, Vienna Breast Cancer
(metastatic)
4.07
Follicular Lymphoma
Rectal Cancer
2006, Istanbul Breast Cancer (adjuvant) 4.24
NSCLC
Hodgkin’s Lymphoma
2008, Stockholm Thrombosis and Cancer 4.48
Pregnancy and Cancer
Gastric Cancer
2009, Berlin Cancer Pain NAb
Head and Neck Cancer
Renal Cell Cancer
2010, Milan Breast Cancer (triple
negative)
4.18
GIST
Pancreatic Cancer
2011, Stockholm
(to be held)
Colorectal Cancer –
Melanoma
Bladder Cancer
aOn a scale of 1–5.
bNA, not available.
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